1. Home
  2. CSTL vs VALN Comparison

CSTL vs VALN Comparison

Compare CSTL & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$32.37

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$6.58

Market Cap

653.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
VALN
Founded
2007
2012
Country
United States
France
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
653.3M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CSTL
VALN
Price
$32.37
$6.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$45.50
$15.50
AVG Volume (30 Days)
310.1K
81.9K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$344,229,000.00
N/A
Revenue This Year
$2.42
N/A
Revenue Next Year
$12.69
$93.87
P/E Ratio
N/A
N/A
Revenue Growth
3.66
N/A
52 Week Low
$17.72
$4.75
52 Week High
$44.28
$12.23

Technical Indicators

Market Signals
Indicator
CSTL
VALN
Relative Strength Index (RSI) 54.54 57.83
Support Level $22.88 $5.10
Resistance Level $34.23 $7.31
Average True Range (ATR) 1.54 0.23
MACD -0.42 -0.05
Stochastic Oscillator 23.40 47.78

Price Performance

Historical Comparison
CSTL
VALN

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: